IMMray™ is a technology platform for developing bioinformatics-assisted, blood-based tests with the potential to detect complex diseases earlier and with higher accuracy.
The first application of this technology is IMMray™ PanCan-d which is a blood test designed for early detection of pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC, stage I & II). The test is offered exclusively as a laboratory developed test (LDT) by Immunovia, Inc. in Marlborough, USA. For more information please visit: www.immunoviainc.com.
Immunovia’s test platform is based on advanced bioinformatics, used to single out a few relevant biomarkers that are used to form a unique disease fingerprint for complex diseases such as pancreatic cancer and other cancers.